MassGen Nederlands Hersentumorcentrum Amsterdam copy current research text box

Tannous copyIsabel Arrillaga Romany headshot Mathilde Kouwenhoven copy

Principle Investigators: Dr. Bakhos Tannous, Dr. Isabel Arrillaga-Romany, Dr. Mathilde Kouwenhoven, Dr. Myra van Linde (not pictured)

Disease: Glioblastoma

Research Description: Glioblastomas (GBMs) are the most common and most lethal form of brain cancers in adults. Length of survival following diagnosis is typically 12-15 months, and less than 10% of patients survive beyond 5 years. The standard chemotherapy for GBM is temozolomide (TMZ), but only about half of patients treated with TMZ respond. Dr. Tannous has shown that a combination of TMZ and another generic drug, hydroxyurea, can increase GBM survival rates in mice. He and his collaborator in the Netherlands, Dr. Kouwenhoven, now propose a clinical trial to test this novel combination in humans. This pilot trial seeks to determine the best dose of TMZ/hydroxyurea and will determine the impact of the combination treatment on survival. If successful, results from this clinical trial could lead to a new therapy option for patients suffering from GBM.

CWR Funding Role: Participating funder

CWR Funding Partner: Goldman Philanthropic Partnerships and Anonymous

Click here to sign up for our eNewsletter today!

Please include your Full Name* and Email Address*


If the link above doesn't work, please contact our Admin support at with your Full Name and Email Address to sign up!


Cures Within Reach

134 N. LaSalle, #1130
Chicago, IL 60602

All funds donated to Cures Within Reach may be tax deductible for federal income tax purposes. 

Partnership for Cures DBA Cures Within Reach is recognized by the IRS as a 501(c)3 tax-exempt not-for-profit organization, tax ID 20-3620169.


Saturday the 28th. Copyright 2018 Cures Within Reach.